This is an old revision of this page, as edited by Boghog (talk | contribs) at 06:45, 27 December 2024 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:45, 27 December 2024 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Pharmaceutical compound
Clinical data | |
---|---|
Other names | CRN04894 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
UNII | |
Chemical and physical data | |
Formula | C33H42F3N5O3 |
Molar mass | 613.726 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Atumelnant (CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.
References
- "Atumelnant (CRN04894)". crinetics.com.
- Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |